705 related articles for article (PubMed ID: 33687659)
1. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?
Marvaso G; Corrao G; Oneta O; Pepa M; Zaffaroni M; Corso F; Gandini S; Cecconi A; Zerini D; Mazzola GC; Augugliaro M; Cossu Rocca M; Verri E; Cattani F; La Fauci F; Bergamaschi L; Luzzago S; Mistretta AF; Musi G; Nolè F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Clin Transl Oncol; 2021 Aug; 23(8):1717-1726. PubMed ID: 33687659
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma.
Ranck MC; Golden DW; Corbin KS; Hasselle MD; Liauw SL; Stadler WM; Hahn OM; Weichselbaum RR; Salama JK
Am J Clin Oncol; 2013 Dec; 36(6):589-95. PubMed ID: 22868242
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies.
Zaorsky NG; Lehrer EJ; Kothari G; Louie AV; Siva S
Eur Urol Oncol; 2019 Sep; 2(5):515-523. PubMed ID: 31302061
[TBL] [Abstract][Full Text] [Related]
4. Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study.
Buti S; Bersanelli M; Viansone A; Leonetti A; Masini C; Ratta R; Procopio G; Maines F; Iacovelli R; Ciccarese C; Vitale MG; De Giorgi U; Mucciarini C; Maruzzo M; Prati G; Lattanzi E; Ciammella P; Bruni A; Andreani S; D'Abbiero N
Cancer Treat Res Commun; 2020; 22():100161. PubMed ID: 31677494
[TBL] [Abstract][Full Text] [Related]
5. The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group.
Franzese C; Marvaso G; Francolini G; Borghetti P; Trodella LE; Sepulcri M; Matrone F; Nicosia L; Timon G; Ognibene L; Vinciguerra A; Alongi F; Bortolus R; Corti L; Ramella S; Magrini SM; Livi L; Jereczek-Fossa BA; Scorsetti M; Arcangeli S
Clin Exp Metastasis; 2021 Dec; 38(6):527-537. PubMed ID: 34748125
[TBL] [Abstract][Full Text] [Related]
6. Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT).
Altoos B; Amini A; Yacoub M; Bourlon MT; Kessler EE; Flaig TW; Fisher CM; Kavanagh BD; Lam ET; Karam SD
Radiat Oncol; 2015 Oct; 10():218. PubMed ID: 26510665
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group.
Meyer E; Pasquier D; Bernadou G; Calais G; Maroun P; Bossi A; Theodore C; Albiges L; Stefan D; de Crevoisier R; Hennequin C; Lagrange JL; Grellard JM; Clarisse B; Licaj I; Habrand JL; Carrie C; Joly F
Eur J Cancer; 2018 Jul; 98():38-47. PubMed ID: 29864737
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control.
Stinauer MA; Kavanagh BD; Schefter TE; Gonzalez R; Flaig T; Lewis K; Robinson W; Chidel M; Glode M; Raben D
Radiat Oncol; 2011 Apr; 6():34. PubMed ID: 21477295
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic Radiotherapy for the Treatment of Patients With Oligo-progressive Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor: Data From the Real World.
Gebbia V; Girlando A; DI Grazia A; Fazio I; Borsellino N; Piazza D; Serretta V; Pergolizzi S; Pontoriero A; Firenze A; Valerio MR
Anticancer Res; 2020 Dec; 40(12):7037-7043. PubMed ID: 33288600
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer.
Zhang Y; Schoenhals J; Christie A; Mohamad O; Wang C; Bowman I; Singla N; Hammers H; Courtney K; Bagrodia A; Margulis V; Desai N; Garant A; Choy H; Timmerman R; Brugarolas J; Hannan R
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):367-375. PubMed ID: 31377159
[TBL] [Abstract][Full Text] [Related]
11. The role of stereotactic body radiotherapy in switching systemic therapy for patients with extracranial oligometastatic renal cell carcinoma.
Onal C; Hurmuz P; Guler OC; Yavas G; Tilki B; Oymak E; Yavas C; Ozyigit G
Clin Transl Oncol; 2022 Aug; 24(8):1533-1541. PubMed ID: 35119653
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic body radiotherapy and tyrosine kinase inhibitors in patients with oligometastatic renal cell carcinoma: a multi-institutional study.
Onal C; Oymak E; Guler OC; Tilki B; Yavas G; Hurmuz P; Yavas C; Ozyigit G
Strahlenther Onkol; 2023 May; 199(5):456-464. PubMed ID: 36450836
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R
Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic Body Radiation Therapy for Oligometastatic Ovarian Cancer: A Step Toward a Drug Holiday.
Lazzari R; Ronchi S; Gandini S; Surgo A; Volpe S; Piperno G; Comi S; Pansini F; Fodor C; Orecchia R; Tomao F; Parma G; Colombo N; Jereczek-Fossa BA
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):650-660. PubMed ID: 29893277
[TBL] [Abstract][Full Text] [Related]
15. Metastasis-directed stereotactic body radiotherapy for oligometastatic renal cell carcinoma: extent of tumor burden eradicated by radiotherapy.
Liu Y; Long W; Zhang Z; Zhang Z; Mai L; Huang S; Han H; Zhou F; Dong P; He L
World J Urol; 2021 Nov; 39(11):4183-4190. PubMed ID: 34043023
[TBL] [Abstract][Full Text] [Related]
16. Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant?
Amini A; Altoos B; Bourlon MT; Bedrick E; Bhatia S; Kessler ER; Flaig TW; Fisher CM; Kavanagh BD; Lam ET; Karam SD
Pract Radiat Oncol; 2015; 5(6):e589-e596. PubMed ID: 26142027
[TBL] [Abstract][Full Text] [Related]
17. Additional chemotherapy improved local control and overall survival after stereotactic body radiation therapy for patients with oligo-recurrence.
Nakamura M; Hashimoto N; Mayahara H; Uezono H; Harada A; Nishikawa R; Matsuo Y; Kawaguchi H; Nishimura H
Radiat Oncol; 2018 Apr; 13(1):75. PubMed ID: 29688858
[TBL] [Abstract][Full Text] [Related]
18. Treatment Outcomes of Stereotactic Body Radiotherapy in Patients with Synchronous and Metachronous Oligometastatic Renal Cell Carcinoma.
Guler OC; Oymak E; Hurmuz P; Yavas G; Tilki B; Yavas C; Ozyigit G; Onal C
Urol Int; 2023; 107(2):171-178. PubMed ID: 36455527
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic Body Radiation Therapy for Mediastinal and Hilar Lymph Node Metastases.
Shahi J; Poon I; Ung YC; Tsao M; Bjarnason GA; Malik NH; Zhang L; Louie AV; Cheung P
Int J Radiat Oncol Biol Phys; 2021 Mar; 109(3):764-774. PubMed ID: 33115687
[TBL] [Abstract][Full Text] [Related]
20. Ten-Year Outcomes of Stereotactic Body Radiotherapy for Oligometastatic Breast Cancer: Does Synchronous Oligometastatic Breast Cancer Benefit?
Nagpal SK; Khabra K; Ross G; Kirby AM
Clin Oncol (R Coll Radiol); 2023 Nov; 35(11):736-743. PubMed ID: 37684189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]